Explore
Validate
LearnMAB3838
antibody from Abnova Corporation
Targeting: CD44
CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB3838 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#MAB3838, RRID:AB_10550083
- Product name
- CD44 monoclonal antibody, clone MEM-263
- Antibody type
- Monoclonal
- Description
- Mouse monoclonal antibody raised against native CD44.
- Isotype
- IgG
- Antibody clone number
- MEM-263
- Storage
- Store at 4°C. Do not freeze.
Submitted references Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival.
HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.
CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.
Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells.
Qin J, Yang B, Xu BQ, Smithc A, Xu L, Yuan JL, Li L
International journal of clinical and experimental pathology 2014;7(6):3235-44
International journal of clinical and experimental pathology 2014;7(6):3235-44
HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.
Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J, Fuchs J, Simeone DM, Chen ZN, Lawrence TS, Xu L
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Dec 15;19(24):6703-15
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Dec 15;19(24):6703-15
CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.
Subramaniam V, Vincent IR, Gardner H, Chan E, Dhamko H, Jothy S
Experimental and molecular pathology 2007 Oct;83(2):207-15
Experimental and molecular pathology 2007 Oct;83(2):207-15
Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells.
Subramaniam V, Gardner H, Jothy S
Experimental and molecular pathology 2007 Dec;83(3):341-6
Experimental and molecular pathology 2007 Dec;83(3):341-6
No comments: Submit comment
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Western Blotting analysis (non-reducing conditions) of isolated peripheral blood lymphocytes (PBL) of various species using CD44 monoclonal antibody, clone MEM-263 (Cat # MAB3838).Lane 1 : Lysate of human PBL.Lane 2 : Lysate of canine PBL.Lane 3 : Lysate of porcine PBL.
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- HepG2 cells were stained with CD44-FITC labeled monoclonal antibody (Green). The cell nucleus were counterstained with DAPI (Blue).
- Validation comment
- Immunofluorescence (Circulating Tumor Cell)
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Immunofluorescence of monoclonal antibody to CD44 on HepG2 cell. [antibody concentration 10 ug/ml]
- Validation comment
- Immunofluorescence
- Protocol
- Protocol
